Abcellera Biologics Inc ABCL

$13.75 -0.16 (-1.15%)

Valuation

Market cap
4,473,455,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
PE ratio
0.00
Forward PE
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
2,241,828
Avg volume
7,064,422
Day's range
$13.83 – $14.30
Shares out
306,611,000
Stochastic %K
66%
Beta
1.32
Analysts
Strong Sell
Price target
$16.70

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

PolarBear1 Oct 2, 2:27 PM
$ABCL With an over $1T market cap, why doesn’t Eli Lily $LLY just offer to buy $ABCL ? Maybe not quite there yet?! Could easily be worth 10x from these prices in <10 years……IMHO
3 replies
Ckkung71 Oct 2, 1:54 PM
$ABCL
0 replies
Rastafari Oct 2, 1:40 AM
$ABCL I love the JP Morgan upgrade and especially the physician survey they conducted! The central thesis is that ABCL has reached a major value inflection point following the encouraging ABCL635 Phase 2 data for menopausal hot flashes. J.P. Morgan highlighted ABCL635’s potentially differentiated profile—particularly its efficacy, safety and dosing convenience—and cited a September physician survey in which roughly 60% of respondents said they could see at least 25% of their menopausal hot-flash patients using ABCL635, with the average expected penetration around 38%. The firm also emphasized AbCellera’s extensive pharmaceutical partnerships as validation of its antibody-discovery platform while helping offset development costs. When JP and Goldman starts coverage, you know there is money to be made!
1 replies
ITF Oct 1, 8:12 PM
$ABCL is this the cup we should be looking forward for the next 12 months, have all the good news and expectations been factored in and now ABCL will need to show they can execute ?
1 replies
erpy Oct 1, 8:09 PM
$ABCL I think a decent presentation. These 3 slides catch what I liked best. Results vs Placebo were strong and liked the sleep improvement slide. Think this a nice hold or buy from here. Jmho.
0 replies
Plan2TradeTrade2Plan Oct 1, 7:26 PM
$ABCL don’t rebound from $13.79 and finish red! 😃 🚀🚀
0 replies
Targhee Oct 1, 6:44 PM
$ABCL impressive
0 replies
Ckkung71 Oct 1, 6:21 PM
$ABCL They shorter trade it back and forth now so watch up don’t try to penny trade. just sitt still don’t let them foul you.
0 replies